Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02830282 · ClinicalTrials.gov registry record
Surveillance Markers of Utility for Recurrence After Neoadjuvant Chemotherapy for Breast Cancer
A clinical trial, sponsored by Abramson Cancer Center at Penn Medicine.
- Completed
- Registry status
- 21
- Enrollment target
NCT02830282 is a clinical trial that has completed, run by Abramson Cancer Center at Penn Medicine. The registered enrollment target is 21 participants.
The verdict
NCT02830282 has completed, sponsored by Abramson Cancer Center at Penn Medicine.
- COMPLETED
- Registry status
- 21 participants
- Enrollment target
Study Summary
This is a nested multicenter, prospective cohort study within the I-SPY 2 TRIAL for women undergoing neoadjuvant chemotherapy for primary breast cancer who are also undergoing definitive surgical resection and have clinical or radiographic evidence of residual tumor at the completion of chemotherapy.
Interventions
- OTHER Blood Collection
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2013-07 |
| Est. Completion | 2018-03-16 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02830282
The ClinicalTrials.gov registry entry for NCT02830282 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Abramson Cancer Center at Penn Medicine, which has 402 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Blood Collection is the first listed.
NCT02830282 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02830282 about?
NCT02830282 is a clinical study titled "Surveillance Markers of Utility for Recurrence After Neoadjuvant Chemotherapy for Breast Cancer". This is a nested multicenter, prospective cohort study within the I-SPY 2 TRIAL for women undergoing neoadjuvant chemotherapy for primary breast cancer who are also undergoing definitive surgical resection and have clinical or radiographic evidence of residual tumor at the completion of chemotherapy...
What is the current status of trial NCT02830282?
This trial is currently completed. The enrollment target is 21 participants. The study started on 2013-07. Estimated completion is 2018-03-16.
What interventions are being tested in trial NCT02830282?
The interventions under investigation include: Blood Collection (OTHER).
Who is sponsoring clinical trial NCT02830282?
This trial is sponsored by Abramson Cancer Center at Penn Medicine, which has 402 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.